Tianjin Chase Sun Pharmaceutical Co.,Ltd's (SZSE:300026) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Tianjin Chase Sun Pharmaceutical Co.,Ltd's (SZSE:300026) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
With its stock down 17% over the past three months, it is easy to disregard Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026). However, stock prices are usually driven by a company's financials over the long term, which in this case look pretty respectable. Specifically, we decided to study Tianjin Chase Sun PharmaceuticalLtd's ROE in this article.
在过去的三个月中,天津追日医药股份有限公司(SZSE:300026)的股票下跌了17%,很容易忽视。然而,股票价格通常受公司长期财务状况的影响,而在这种情况下,状况看起来相当可观。具体而言,在本文中,我们决定研究天津追日医药股份有限公司的roe。
Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors' money. Simply put, it is used to assess the profitability of a company in relation to its equity capital.
股东权益回报率(ROE)是测试公司如何有效地增加其价值并管理投资者资金的指标。简而言之,它用于评估公司相对于股本资本的盈利能力。
How Is ROE Calculated?
净资产收益率怎么计算?
ROE can be calculated by using the formula:
净资产收益率可以使用以下公式进行计算:
Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity
净资产收益率 = 净利润(从持续经营中获得)÷ 股东权益
So, based on the above formula, the ROE for Tianjin Chase Sun PharmaceuticalLtd is:
因此,根据上述公式,天津追日医药股份有限公司的roe为:
4.2% = CN¥377m ÷ CN¥8.9b (Based on the trailing twelve months to March 2024).
4.2% = CN¥377m÷CN¥8.9b(基于截至2024年3月的过去十二个月)。
The 'return' is the yearly profit. One way to conceptualize this is that for each CN¥1 of shareholders' capital it has, the company made CN¥0.04 in profit.
“回报”是每年的利润。一种概念化的方式是,对于每个CN¥1的股东资本,公司的利润为CN¥0.04。
What Is The Relationship Between ROE And Earnings Growth?
既然我们已经确定ROE是一种有效的利润生成标准,用于评估公司未来的盈利能力,我们现在需要评估公司“保留”为未来增长而重新投资的利润多少,这使我们对公司的增长潜力有了一个了解。一般而言,在其他条件相等的情况下,ROE和利润留存高的公司,增长率比没有这些属性的公司要高。
So far, we've learned that ROE is a measure of a company's profitability. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics.
到目前为止,我们已经了解到ROE是一家公司盈利能力的衡量标准。基于公司选择重新投资或“保留”的利润的数量,我们随后能够评估公司未来产生利润的能力。假设其他所有条件不变,ROE和利润保留越高,增长率就相对较高,与那些可能不具备这些特征的公司相比,增长更快。
A Side By Side comparison of Tianjin Chase Sun PharmaceuticalLtd's Earnings Growth And 4.2% ROE
天津追日医药股份有限公司的盈利增长和4.2%的roe的并列比较
As you can see, Tianjin Chase Sun PharmaceuticalLtd's ROE looks pretty weak. Not just that, even compared to the industry average of 7.7%, the company's ROE is entirely unremarkable. Although, we can see that Tianjin Chase Sun PharmaceuticalLtd saw a modest net income growth of 12% over the past five years. We believe that there might be other aspects that are positively influencing the company's earnings growth. For example, it is possible that the company's management has made some good strategic decisions, or that the company has a low payout ratio.
正如您所看到的,天津追日医药股份有限公司的roe看起来相当薄弱。不仅如此,甚至与行业平均roe 7.7%相比,公司的roe也毫不显著。尽管如此,我们可以看到天津追日医药股份有限公司过去五年的净利润增长率略微增长了12%。我们认为,可能有其他方面正面影响着公司的盈利增长,例如,公司的管理层做出了一些良好的战略决策,或者公司的派息比率很低。
As a next step, we compared Tianjin Chase Sun PharmaceuticalLtd's net income growth with the industry, and pleasingly, we found that the growth seen by the company is higher than the average industry growth of 9.2%.
下一步,我们将天津追日医药股份有限公司的净利润增长与行业进行比较,令人高兴的是,我们发现公司的增长率高于平均行业增长率9.2%。
![past-earnings-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240611/0-d142ddab47267a683d50ee7d6592920d-0-18d8268ff42783f7b9c3fb89ebb649b7.png/big)
Earnings growth is an important metric to consider when valuing a stock. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. Doing so will help them establish if the stock's future looks promising or ominous. One good indicator of expected earnings growth is the P/E ratio which determines the price the market is willing to pay for a stock based on its earnings prospects. So, you may want to check if Tianjin Chase Sun PharmaceuticalLtd is trading on a high P/E or a low P/E, relative to its industry.
盈利增长是估值股票时要考虑的重要指标。投资者应该努力确定是否定价了预期的盈利增长或下降,无论哪种情况,这将有助于他们确定股票的未来前景是充满希望还是不祥之兆。预期盈利增长的一个很好的指标是市盈率,该指标根据公司的盈利前景确定市场愿意为一只股票支付的价格。因此,您可能需要检查天津追日医药股份有限公司的市盈率高还是低,相对于其行业而言。
Is Tianjin Chase Sun PharmaceuticalLtd Efficiently Re-investing Its Profits?
天津追日医药股份有限公司是否有效地再投资其利润?
Tianjin Chase Sun PharmaceuticalLtd has a low three-year median payout ratio of 17%, meaning that the company retains the remaining 83% of its profits. This suggests that the management is reinvesting most of the profits to grow the business.
天津追日医药股份有限公司的三年中位数派息比率较低,为17%,这意味着公司保留了其余83%的利润。这表明管理层正在将大部分利润再投资以促进业务增长。
Besides, Tianjin Chase Sun PharmaceuticalLtd has been paying dividends for at least ten years or more. This shows that the company is committed to sharing profits with its shareholders.
此外,天津追日医药股份有限公司在过去至少十年支付分红派息。这表明该公司致力于与股东共享利润。
Summary
总的来说,我们对伟明环保的表现非常满意。具体而言,我们喜欢公司以高回报率再投资了其利润的很大一部分。当然,这导致公司的收益大幅增长。但是,最新的行业分析师预测表明,该公司的收益预计将加速增长。
On the whole, we do feel that Tianjin Chase Sun PharmaceuticalLtd has some positive attributes. With a high rate of reinvestment, albeit at a low ROE, the company has managed to see a considerable growth in its earnings. With that said, the latest industry analyst forecasts reveal that the company's earnings are expected to accelerate. To know more about the company's future earnings growth forecasts take a look at this free report on analyst forecasts for the company to find out more.
总的来说,我们确实认为天津追日医药股份有限公司具有一些积极的属性。尽管roe较低,但在高比率再投资的情况下,该公司成功实现了盈利的相当增长。话虽如此,最新的行业分析师预测显示,公司的盈利有望加速增长。要了解有关公司未来盈利增长预测的更多信息,请查看有关该公司的分析师预测的免费报告。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈?关于内容有所顾虑?直接和我们联系。或者,发送电子邮件至editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。